Filter by Event: ASM Microbe 2016
In Vitro Antibacterial Activity of WCK 5999: A New Carbapenem/β-lactamase Inhibitor Combination against ESBL-Phenotype and Carbapenemase Producing Enterobacteriaceae from a Worldwide Surveillance Program (2015)
In Vitro Antibacterial Activity of WCK 5999: A New Carbapenem/β-lactamase Inhibitor Combination against ESBL-Phenotype and Carbapenemase Producing Enterobacteriaceae from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-425
Activity of the New Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates Producing Oxacillinases(OXAs)
Activity of the New Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates Producing Oxacillinases (OXAs), Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-422
In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae
In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-421
In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015)
In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-476
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-447
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Antimicrobial Resistant Gram-negative Bacilli
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Antimicrobial Resistant Gram-negative Bacilli, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-446
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Enterobacteriaceae Clinical Isolates Collected Worldwide (2015)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Enterobacteriaceae Clinical Isolates Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-445
Antimicrobial Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter spp. Collected Worldwide (2015)
Antimicrobial Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter spp. Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-478
WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases
WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-477
In Vitro Activity of Lactone Ketolide WCK 4873 When Tested Against Contemporary Community-Acquired Bacterial Pneumonia Pathogens from a Global Surveillance Program
In Vitro Activity of Lactone Ketolide WCK 4873 When Tested Against Contemporary Community-Acquired Bacterial Pneumonia Pathogens from a Global Surveillance Program, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-476
In Vitro Activity of WCK 4873 (Nafithromycin) against Resistant Subsets of Streptococcus pneumoniae From a Global Surveillance Program (2014)
In Vitro Activity of WCK 4873 (Nafithromycin) against Resistant Subsets of Streptococcus pneumoniae From a Global Surveillance Program (2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-455
WCK 4282 (High-Dose Cefepime-Tazobactam) Disk Diffusion Quality Control Ranges Using a Multi-laboratory Study Design
WCK 4282 (High-Dose Cefepime-Tazobactam) Disk Diffusion Quality Control Ranges Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-018
Enhanced Activity of WCK 4282 (Cefepime-Tazobactam) Against KPC-Producing Enterobacteriaceae Collected Worldwide When Tested in Physiological Conditions
Enhanced Activity of WCK 4282 (Cefepime-Tazobactam) Against KPC-Producing Enterobacteriaceae Collected Worldwide When Tested in Physiological Conditions, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-427
In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program
In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program, Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-456
Activity of Telavancin Against a Global Collection of Staphylococcus aureus Causing Bacteremia (2011-2014)
Activity of Telavancin Against a Global Collection of Staphylococcus aureus Causing Bacteremia (2011-2014), Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-335
Activity of TelavancinAgainst Gram-positive Pathogens Isolated from Bone and Joint Infections in North American, Latin American, European and Asia-Pacific Nations
Activity of TelavancinAgainst Gram-positive Pathogens Isolated from Bone and Joint Infections in North American, Latin American, European and Asia-Pacific Nations, Lead author: Jones RN, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-445
Synergistic Effect of Gram-positive Agents Tested in Combination with a New Polymyxin Derivative (SPR741) against Multidrug-resistant Gram-negative Pathogens
Synergistic Effect of Gram-positive Agents Tested in Combination with a New Polymyxin Derivative (SPR741) against Multidrug-resistant Gram-negative Pathogens, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-490
S-649266 MIC Quality Control Ranges in Iron-depleted cation-adjusted Mueller-Hinton Broth Using a Multi-laboratory Study Design
S-649266 MIC Quality Control Ranges in Iron-depleted cation-adjusted Mueller-Hinton Broth Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-028
Oritavancin Longitudinal In Vitro Activity Against Gram-positive Organisms from USA Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
Oritavancin Longitudinal In Vitro Activity Against Gram-positive Organisms from USA Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010-2014, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-345
Meropenem-vaborbactam (MER-VAB) Tested Against Contemporary Enterobacteriaceae Isolates from USA Hospitals
Meropenem-vaborbactam (MER-VAB) Tested Against Contemporary Enterobacteriaceae Isolates from USA Hospitals, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-452
Evolving Linezolid Resistance Mechanisms in a Worldwide Collection of Enterococcal Clinical Isolates: Results from the SENTRY Antimicrobial Surveillance Program
Evolving Linezolid Resistance Mechanisms in a Worldwide Collection of Enterococcal Clinical Isolates: Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-332
Gepotidacin (GSK2140944) In Vitro Activity Against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME Tests)
Gepotidacin (GSK2140944) In Vitro Activity Against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-461
Gepotidacin (GSK2140944) In Vitro Activity Against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME Tests)
Gepotidacin (GSK2140944) In Vitro Activity Against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-460
In vitro Activity of Delafloxacin When Tested Against Contemporary Bacterial Pathogens from the USA (2014)
In vitro Activity of Delafloxacin When Tested Against Contemporary Bacterial Pathogens
from the USA (2014), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-457
Activity of Ceftazidime-Avibactam Tested against Clinical Isolates of Antimicrobial Resistant Pseudomonas aeruginosa from United States Medical Centers (2012-2014)
Activity of Ceftazidime-Avibactam Tested against Clinical Isolates of Antimicrobial Resistant Pseudomonas aeruginosa from United States Medical Centers (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-436
Ceftazidime-Avibactam Antimicrobial Activity When Tested against Gram-negative Bacteria Isolated from Intensive Care Unit (ICU) Patients with Pneumonia (2012-2014)
Ceftazidime-Avibactam Antimicrobial Activity When Tested against Gram-negative Bacteria Isolated from Intensive Care Unit (ICU) Patients with Pneumonia (2012-2014). Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-434
Ceftazidime-Avibactam Activity Tested against Eleven Enterobacteriaceae Species Producing KPC Enzymes
Ceftazidime-Avibactam Activity Tested against Eleven Enterobacteriaceae Species Producing KPC Enzymes, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-451
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014)
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-435
